Latest Cost Management News

MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Latitude 66 Ltd posted a $1.75 million net cash outflow for the December quarter, ending with $2.18 million in cash reserves. The company anticipates lower costs ahead and intends to sell shares valued at around $850,000 to fund ongoing activities.

Bannerman Energy reports solid progress on its Etango Uranium Project with construction milestones met, a robust cash position, and a bullish uranium market backdrop.

Bannerman Energy reported a substantial $14.17 million cash outflow in its December quarter, driven by aggressive exploration and evaluation investments, leaving the company with $81.1 million in cash reserves.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Wrkr Ltd reports strong commercial progress and strategic hires in Q2 FY25, positioning itself for growth with key platform enhancements and pilot completions ahead of Payday Super implementation.

InVert Graphite Limited has secured shareholder approval for a transformative acquisition of a Tanzanian graphite project and rebranded from Dominion Minerals, positioning itself for a strategic relisting on the ASX.

Grand Gulf Energy Limited reports steady oil production and strategic progress on its helium projects, including a planned 3D seismic survey and ongoing funding discussions, while implementing cost controls in a softening market.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

CurveBeam AI Limited reported a remarkable 150% increase in device purchase orders in Q2 FY25, driven by strong demand for its HiRise™M platform and a new commercial agreement with Stryker. The company is advancing validation of its Enhanced HiRise™ for robotic surgical systems, despite a regulatory delay for its BMD SaaS module.

Syntara Limited reported a robust $11.35 million increase in cash during the December 2024 quarter, underpinned by government grants and steady operational inflows. The company closes the period with a strong cash position of $18.07 million, signaling financial resilience.